Founded in 2008, the company is based in Charleston, South Carolina. It focuses on creating and manufacturing antibody-based treatments for a variety of biological targets, including human monoclonal antibodies targeting viral, bacterial, and tumor antigens, as well as human auto antigens.
The company recently received a $250.95K Seed Round investment on 20 July 2011. This funding will likely contribute to further advancements in their research and development efforts. Immunologix, Inc. is positioned at the forefront of the biotechnology and pharmaceutical industries, with potential for significant growth and impact in the field of antibody therapeutics.
